DBV Technologies Shares Drop Nearly 4% Following a Challenging Month
The French biotech company sees a significant midday decline in a mostly stable SBF 120 market. The stock approaches a closely watched technical threshold, two days before its mixed general meeting.
Technical Analysis: Below MM20 and MM50, the €3.19 Support Level Remains Critical
DBV Technologies' stock falls 3.81% to €3.23 at midday, marking one of the steepest declines in the SBF 120, while the broader index slightly gains 0.10%. The stock has significantly dropped below its MM20 (€3.33) and MM50 (€3.45), with a 6.3% gap below the latter, indicating that the short-term momentum remains weak. The price is now approaching the support level at €3.19, previously identified as a reaction zone in an earlier analysis. The RSI at 51 remains neutral, showing no signs of seller exhaustion. The MM200 at €2.94 still provides a cushion of nearly 10%, reflecting the sustained rebound over the year: the stock is up +116% over twelve months, despite a nearly 10% decline over three months.
Short Interest Increases as Institutional Investors Apply Downward Pressure
Recent statements indicate that two funds now cumulatively hold 2.90% of the capital sold short on the stock. This position has expanded by 1.40 points in a month, from 1.50% thirty days ago. This rapid increase reflects rising downward pressure from institutional investors, although this should not necessarily be seen as a negative consensus: the affected float remains limited and this issue should be monitored alongside other signals in the file. The calendar provides a concrete upcoming event with the mixed general meeting scheduled for Wednesday, June 3. Strategically, 2026 remains a pivotal year for the biotech with two expected FDA filings for the Viaskin Peanut patch, as previously mentioned in a publication.
